Interchangeability of hepatitis A vaccines
Not Applicable
- Conditions
- Hepatitis A
- Registration Number
- JPRN-UMIN000009351
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Aimmugen is a lyophilized inactivated aluminum-free hepatitis A vaccine (0, 2-4 weeks and 6 months). Participants were twenty healthy Japanese travelers aged 20 years or older who had received two doses of Aimmugen. They received a booster dose of Havrix1440 intramuscularly as the third dose. The seroprotection rate was 85 % at pre-vaccination, and 100 % at post-vaccination of Havrix. The geometric mean antibody titers increased from 39.8 mIU/mL to 2938 mIU/mL.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
acute febrile illness immunodeficiency allergy against vaccine contents pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anti-HAV antibody: Anti-HAV antibody will be measured on days 0 and 28 after vaccination of Havrix.
- Secondary Outcome Measures
Name Time Method Adverse event: Averse events will be documented by the subjects.